Skip to main content
. 2020 Jan 28;21(3):838. doi: 10.3390/ijms21030838

Table 2.

Performance of BDX008 and immune checkpoint blockade (ICB) tests in development cohort.

Test BDX008 ICB
Classification BDX008+ BDX008– ICB Sensitive ICB Resistant
n (%) 72 (61%) 47 (39%) 34 (29%) 85 (71%)
2-year survival 55% 21% 67% 33%
3-year survival 51% 14% 58% 28%
OS curves comparison HR = 0.38 (0.19–0.55), p < 0.001 HR = 0.37 (0.19–0.71), p = 0.002

OS: Overall survival. HR: hazard ratio.